Skip to main content
SpringerLink
Log in

Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

There is no standard therapy for recurrent anaplastic astrocytoma (AA). Assess response and toxicity of lomustine (CCNU) in recurrent AA following prior surgery, radiotherapy and TMZ in a retrospective case series. Thirty-five adults (18 males; 17 females: median age 42.5 years) with TMZ refractory recurrent AA were treated with lomustine. Seven patients were treated at 1st recurrence and 28 patients were treated at 2nd recurrence. Prior salvage therapy included re-resection in 19, TMZ in 20 and radiotherapy in 7. A cycle of lomustine was defined as 110 mg/m2 on day 1 only administered once every 6–8 weeks. Success of treatment was defined as progression free survival at 6 months of 40 % or better. Grade 3 or 4 toxicities included anemia (14 patients), constipation (1), fatigue (4), lymphopenia (5), nausea/vomiting (2), neutropenia (8) and thrombocytopenia (10). No grade five toxicities were seen. The median number of cycles of therapy was 3 (range 1–6). Best radiographic response was progressive disease in 14 (40 %), stable disease in 19 (54 %) and partial response in 2 (5.7 %). Median progression free survival (PFS) was 4.5 months (range 1.5–12 months), 6-month PFS was 40 % and 12 month PFS was 11.4 %. Median survival after onset of CCNU was 9.5 months (range 2.5–15 months). Median overall survival was 2.7 years (range 1.7–4.3). In this small retrospective series of patients with recurrent AA refractory to TMZ, lomustine appears to have modest single agent with manageable toxicity. Confirmation in a larger series of similar patients is required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Prados MD, Gutin PH, Phillips TL et al (1992) Anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 23:3–8

    Article  CAS  PubMed  Google Scholar 

  2. Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451

    Article  CAS  PubMed  Google Scholar 

  3. Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718

    Article  PubMed  Google Scholar 

  4. Cairncross JG, Wang M, Jenkins RB et al (2014) Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH. J Clin Oncol 32:783–790

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Nabors LB, Ammirati M, Bierman PJ et al (2013) Central nervous system cancers. J Natl Compr Cancer Netw 11:1114–1151

    CAS  Google Scholar 

  6. Weller M, van den Bent M, Hopkins K et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15:e395–e403

    Article  PubMed  Google Scholar 

  7. Cairncross G, Wang M, Shaw E et al (2013) Phase III Trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. van den Bent MJ, Brandes AA, Taphoorn MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350

    Article  PubMed  Google Scholar 

  9. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine and vincristine or temozolomide. J Clin Oncol 27:5874–5880

    Article  CAS  PubMed  Google Scholar 

  10. Stupp R, Mason WP, van den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  11. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008–1012

    Article  CAS  PubMed  Google Scholar 

  12. Combs SE, Thilmann C, Edler L et al (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869

    Article  PubMed  Google Scholar 

  13. Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053

    Article  PubMed Central  PubMed  Google Scholar 

  14. Perry JR, Belanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051–2057

    Article  CAS  PubMed  Google Scholar 

  15. Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain tumor group. J Clin Oncol 17:2762–2771

    CAS  PubMed  Google Scholar 

  16. Brada M, Stenning S, Gabe R et al (2010) Temozolomide versus procarbazine, lomustine and vincristine in recurrent high-grade glioma. J Clin Oncol 28:4601–4608

    Article  CAS  PubMed  Google Scholar 

  17. Yung WKA, Kyritsis AP, Gleason MJ, Levin VA (1992) Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 2:1931–1935

    Google Scholar 

  18. Chamberlain MC, Kormanik P (1999) Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J Clin Oncol 43:71–78

    CAS  Google Scholar 

  19. Chamberlain M, Tsao-Wei D, Blumenthal D, Glantz MJ (2008) Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer 112:2038–2045

    Article  CAS  PubMed  Google Scholar 

  20. Chamberlain MC, Tsao-Wei D, Groshen S (2006) Salvage chemotherapy with cyclophosphamide for temozolomide refractory anaplastic astrocytoma. Cancer 106:172–179

    Article  CAS  PubMed  Google Scholar 

  21. Levin VA, Prados MD (1992) Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosoureas resistance. J Clin Oncol 10:766–771

    CAS  PubMed  Google Scholar 

  22. Levin VA, Prados MD, Yung WKA, Gleason MJ, Ictech S, Malec M (1992) Treatment of recurrent gliomas with enflornithine. J Natl Cancer Inst 84:1432–1437

    Article  CAS  PubMed  Google Scholar 

  23. Jaeckle KA, Hess KR, Yung WK et al (2003) Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American brain tumor consortium study. J Clin Oncol 1:2305–2311

    Article  Google Scholar 

  24. Levin VA, Ictech S, Hess KR (2007) Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMJ Cancer 7:106–113

    Article  Google Scholar 

  25. Walbert T, Gilbert MR, Groves MD et al (2011) Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol 102:273–280

    Article  CAS  PubMed  Google Scholar 

  26. Kyritsis AP, Levin VA (2011) An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 67:971–983

    Article  CAS  PubMed  Google Scholar 

  27. Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK (1999) Response and progression in recurrent malignant glioma. Neuro Oncol 1:282–288

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Desjardins A, Quinn JA, Vredenburgh JJ et al (2007) Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83:53–60

    Article  CAS  PubMed  Google Scholar 

  29. Kyritsis AP, Yung WK, Jaeckle KA et al (1999) Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurg 39:921–926

    Google Scholar 

  30. Kunschner LJ, Yung WKA, Levin VA, Jaeckle KA (1999) Carboplatin and 13-cis-retinoic acid for recurrent glioblastoma multiforme. Neuro-Oncol 1:320–325

    Google Scholar 

  31. Franceschi E, Bartolotti M, Dall’Occa P et al (2012) Anaplastic glioma at first recurrence: outcome analysis. J Clin Oncol 30(suppl.):2061 (abstract)

  32. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787

    Article  CAS  PubMed  Google Scholar 

  33. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740

    Article  CAS  PubMed  Google Scholar 

  34. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Desjardins A, Reardon DA, Herndon JE 2nd et al (2008) Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14:7068–7073

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Wick W, Puduvalli VK, Chamberlain MC et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–1174

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Batchelor T, Mulholland P, Neyns B et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–3218

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. MacDonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    CAS  PubMed  Google Scholar 

  39. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972

    Article  PubMed  Google Scholar 

  40. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578

    CAS  PubMed  Google Scholar 

  41. Lamborn KR, Yung AWK, Chang SM et al (2008) Progression free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. J Neurooncol 10:162–170

    Google Scholar 

  42. Chamberlain MC, Johnston S (2009) Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neuro-Oncol 91:359–367

    Article  CAS  Google Scholar 

  43. Kreisl TN, Zhang W, Odia Y et al (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-Oncol 13:1143–1150

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Reardon DA, Desjardins A, Vredenburgh JJ et al (2009) Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101:1986–1994

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al (2010) Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncol 12:1300–1310

    PubMed Central  CAS  PubMed  Google Scholar 

  46. Seystahl KL, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A (2013) Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 69:95–101

    Article  CAS  PubMed  Google Scholar 

  47. Delios A. Brebnnan CW, Huse JT, Colevas K, Omuro AMP (2012) Bevacizumab for recurrent WHO grade III anaplastic glioma (AG). J Clin Oncol 30(suppl.):2028 (abstract)

Download references

Acknowledgments

Author information

Authors and Affiliations

  1. Division of Neuro-Oncology, Department of Neurology and Neurological Surgery, University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, MS: G4-940, Seattle, WA, 98109, USA

    Marc C. Chamberlain

Authors
  1. Marc C. Chamberlain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc C. Chamberlain.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chamberlain, M.C. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. J Neurooncol 122, 329–338 (2015). https://doi.org/10.1007/s11060-014-1714-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1714-9

Keywords

Search

Navigation